Technikos is a London based venture capital fund specialising in medical technology. In 2006, Technikos entered into a formal, long-term commercial partnership with Oxford University’s Institute of Biomedical Engineering (IBME).  Under the terms of this agreement, Technikos receives half the University’s equity in any biomedical spin-out from the IBME, along with half the University’s share of any IBME-derived royalties from licensing income also.

The IBME, which opened in January 2008, is located opposite Oxford’s Churchill Hospital, and offers a centralised venue for engineers, biologists and clinicians to work together and to coordinate expertise, discoveries and best practice in order to enhance the diagnosis and treatment of a range of conditions.

It builds upon the historic world-class strengths of Oxford’s Department of Engineering Science in medical engineering, with companies such as Powderject (now part of Novartis) and Mirada Solutions (now part of Siemens). It provides purpose-built laboratories, shared common support facilities, a core of securely funded staff, the latest equipment for research and development and the right setting to promote collaboration among medical, biological and physical scientists and engineers.

The Institute also directly benefits from close proximity to the Oxford Centre for Cancer Medicine, the Department of Clinical Pharmacology, the Radiation Oncology and Biology Unit, the Jenner Institute and the Wellcome Centre for Human Genetics.

The Institute is focused on bio-medical image analysis, bio-medical signal processing, bio-medical ultrasonics, drug and vaccine delivery, fluid mechanics, orthopaedics bio-medical engineering and tissue engineering and bio-processing

Technikos benefits not just in terms of preferential access to deal flow and but also ready access to broad based academic and commercial expertise in the med-tech field.